Company / PP&E (Net)
AVADEL PHARMACEUTICALS PLC PP&E (Net) History
FY2015-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest PP&E (Net)
$453.0K
FY2024
5-year range
$285.0K / $839.0K
FY2020-FY2024
Trend
-22.6%
vs FY2023
Sector context
#171 of 193
Health Care
What the data says
AVADEL PHARMACEUTICALS PLC's pp&e (net) of $453,000 is lower than 89% of companies in the Health Care sector (FY2024). PP&E (Net) has fluctuated over the past 10 years, ranging from $285,000 in FY2021 to $3M in FY2016.
Based on SEC 10-K filings.
$453,000 in FY2024 with a 5-year CAGR of -3.6%.
Declined from $839,000 to $453,000 over the past 2 years.
Health Care sector context is included.
PP&E (Net) over time
Growth rates
- 3-Year CAGR
- +16.7%
- 5-Year CAGR
- -3.6%
- 10-Year CAGR
- -
Sector benchmark
Bottom 11% in Health CareTop 89% of 193This company $453.0K Sector average $777.6M
▼
-99.9% below sector average
Key checks
Key Insights
- 5-year CAGR of -3.6%, indicating a declining trend.
- In FY2024, pp&e (net) decreased 22.6% year-over-year.
- Ranks #171 out of 193 companies in the Health Care sector.
- Peak pp&e (net) was recorded in FY2016.
Company context
Key Data Points
- Altman Z-Score 0.94 (distress zone, below 1.8 threshold)
- Negative profit margin: -28.9%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | PP&E (Net)Value | YoY GrowthYoY |
|---|---|---|
| FY2024 | $453.0K | -22.6% |
| FY2023 | $585.0K | -30.3% |
| FY2022 | $839.0K | +194.4% |
| FY2021 | $285.0K | -20.6% |
| FY2020 | $359.0K | -34.0% |
| FY2019 | $544.0K | -71.5% |
| FY2018 | $1.9M | -36.3% |
| FY2017 | $3.0M | -9.6% |
| FY2016 | $3.3M | +26.9% |
| FY2015 | $2.6M | +47.3% |
As of FY2024 · SEC 10-K · Updated Feb 28, 2026